Galedra

Claims

Search Type State Status Topic Model Order Counting Over

As of snapshot 27745 under ledger-default@0.3.0.

Claim	Type	Assessment	Score	Review checks	References
In the AMP trials, prophylactic VRC01 selected de novo HIV escape mutations in 8 of 26 treated participants but none of 21 placebo participants; several mutations caused cross-resistance, while N6 and 1–18 largely retained activity.	QUANTITATIVE	Insufficient evidence	—	1 of 4	135